The high cost of disease-modifying therapies (DMTs) for multiple sclerosis (MS), and the challenging process of insurance approval, lead to treatment gaps or alterations, increased symptoms, and sacrifices in lifestyle, a survey from the National Multiple Sclerosis Society (NMSS) shows.
“People with MS are paying the price, not only financially, but also physically and emotionally,” Bari Talente, NMSS’s executive vice president of advocacy, said in a press release.
During the past 20 years, many DMTs — those that reduce the activity and progression of a disease — have become available to MS patients. While DMT use has been associated with favorable long-term benefits and fewer hospitalizations, their high cost can be a major obstacle for patients.
A previous study showed that the increased MS annual healthcare costs seen during the past decade in the U.S. are due mainly to the increased cost of DMTs.
To better understand the effects of DMTs’ high costs in the lives of people with MS, the NMSS conducted a national study consisting of an online survey followed by telephone interviews.
Among the 12,000 MS patients invited to the online survey by email, 578 (5%) responded; 96% of them had ever used a DMT and were thus included in the study.
Most of the participants were white, 74% were women, and they had an overall average age of 35.4 years. Three-quarters of them had relapsing-remitting MS, and more than half were diagnosed more than 10 years ago.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?